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Infection of quiescent fibroblasts with human cytomegalovirus (HCMV) was found to cause a rapid activa-
tion of cellular phosphatidylinositol 3-kinase (PI3-K). Maximum PI3-K activation occurred from 15 to 30 min
postinfection. This activation was transient, and by 2 h postinfection (hpi), PI3-K activity had declined to
preinfection levels. However, at 4 hpi, a second tier of PI3-K activation was detected, and PI3-K activity
remained elevated relative to that of mock-infected cells for the remainder of infection. The cellular kinases Akt
and p70S6K and the transcription factor NF-kB were activated in a PI3-K-dependent manner at similar times
following HCMV infection. Analysis using UV-irradiated virus indicated that no viral protein synthesis was
necessary for the first phase of PI3-K activation, but viral protein expression was required for the second tier
of PI3-K activation. Treatment of infected fibroblasts with LY294002, a potent and specific inhibitor of PI3-K
kinase activity, caused a 4-log decrease in viral titers. LY294002 did not inhibit viral entry, but it did decrease
viral immediate-early gene expression. In addition, the protein levels of two viral early genes required for DNA
replication, UL84 and UL44, were significantly lower in the presence of LY294002. Furthermore, viral DNA
replication was strongly inhibited by LY294002 treatment. This inhibition of viral DNA replication could be
reversed by adding back the products of PI3-K activity (PI-3,4-P2 and PI-3,4,5-P3), demonstrating that the
effect of LY294002 on the viral life cycle was specifically due to the inhibition of PI3-K activity. These results
are the first to suggest that PI3-K mediates HCMV-induced activation of host cell mitogenic pathways. They
also provide strong evidence that PI3-K activation is important for initiation of viral DNA replication and
completion of the viral lytic life cycle.
Human cytomegalovirus (HCMV) is a widespread human
pathogen that does not cause significant clinical manifestations
in healthy individuals (29, 32, 50). On the other hand, it causes
severe diseases in immunocompromised individuals that, if left
untreated, can be fatal. In addition, it is a leading cause of
certain types of birth defects (29, 32, 50). Individuals suffering
from diseases caused by HCMV are currently treated with
chemical compounds, such as ganciclovir and phosphocarnet,
which block the viral lytic life cycle by inhibiting viral DNA
replication (48, 51, 66). However, the substantial toxicity of
these drugs and the emergence of drug-resistant strains of
HCMV indicate that better antiviral compounds are needed
(5, 66, 69). Recently, we have begun to identify and character-
ize signal transduction pathways that are activated following
HCMV infection of human fibroblasts. By studying these path-
ways, we hope not only to better understand HCMV patho-
genesis at the molecular level but also to eventually identify
unique, virus-specific targets which can be utilized for the de-
velopment of potent anti-HCMV compounds (33, 34).
Like all herpesviruses, the lytic life cycle of HCMV is a
temporally regulated cascade of events which is initiated when
the virus binds to host cell receptors (50). Following viral entry
and translocation of the viral DNA to the nucleus, viral imme-
diate-early (IE) genes are expressed. Next, early (E) gene
expression occurs, followed by viral DNA replication. After
initiation of viral DNA replication, late (L) genes are ex-
pressed. The viral DNA is then encapsidated and infectious
virus is released from the cell, completing the life cycle.
One hallmark of HCMV infection of quiescent cells is the
up-regulation of many host cell proteins, including DNA rep-
lication enzymes and transcription factors, which are necessary
for both viral gene expression and viral DNA replication (2, 8,
21, 30, 32, 84). Recent studies suggest that host cell kinases
must also be activated before viral DNA replication can begin
(12, 34). For example, the cyclin-dependent kinase 2 (CDK2)
and mitogen-activated protein kinases (MAPK) p38 and
ERK1/2 are all activated following HCMV infection of quies-
cent fibroblasts, and inhibiting the kinase activity of any of
these proteins significantly inhibits viral DNA replication (12,
14, 15, 33, 34, 35).
Phosphatidylinositol 3-kinases (PI3-K) are a cellular family
of heterodimeric enzymes that consist of a regulatory subunit
(p85) and a catalytic subunit (p110) (16, 28, 67, 70). When
activated by phosphorylation on specific, conserved tyrosine
residues, the p85 subunit recruits substrates to the dimer,
where they are phosphorylated by the p110 catalytic subunit
(23, 54, 70). PI3-K is activated by many different mitogenic
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signals, such as epidermal growth factor (70). Upon activation,
PI3-K phosphorylates inositol phospholipids at the D-3 posi-
tion of the inositol ring (46, 73). Once phosphorylated at the
D-3 position, these lipids serve as second messengers and are
able to regulate phosphorylation of a number of kinases, in-
cluding Akt (also known as protein kinase B [PKB]), cyclic
AMP-dependent kinase (PKA), some isoforms of PKC, and
the ribosomal S6 kinases p70 and p85 (p70S6K and p85S6K,
respectively) (23, 73, 75, 76). Because PI3-K controls the acti-
vation of so many different pathways, it is a critical mediator of
many different cellular processes, including cell growth, pro-
tection from different types of apoptosis, cell migration, and
changes in cell morphology (1, 38–40, 44, 49).
The ability of PI3-K to regulate multiple mitogenic path-
ways, coupled with the need for HCMV to induce an environ-
ment favorable for viral DNA synthesis, prompted us to exam-
ine PI3-K signaling during HCMV infection. In this study, we
show that PI3-K is strongly activated immediately following
infection of quiescent fibroblasts with HCMV (15 to 30 min
postinfection). A second tier of PI3-K activation was detected
beginning at 4 h postinfection (hpi) and continuing throughout
the course of infection. PI3-K activity was found to be required
for activation of Akt, p70S6K, and the transcription factor
NF-kB in HCMV-infected fibroblasts. In addition, inhibition
of PI3-K activity dramatically decreased viral titers, at least
partly by inhibiting viral DNA replication. Finally, inhibition of
PI3-K activity decreases the protein levels of viral IE and E
genes required for DNA replication. Collectively, this study
demonstrates that PI3-K activity not only mediates virus-in-
duced signaling following infection but also that this activity is
essential for completion of the HCMV lytic life cycle.
MATERIALS AND METHODS
Chemical compounds. The p38 MAPK kinase inhibitor SB202190 [4-(4-flu-
orophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] (45), rapamycin, an
inhibitor of p70S6K phosphorylation (63, 71), phosphatidylinositol-3,4-bisphos-
phate (PI-3,4-P2 or PtDns 3,4), and phosphatidylinositol-3,4,5-triphosphate (PI-
3,4,5-P3 or PtDns 3,4,5) were from Calbiochem (La Jolla, Calif.). Ganciclovir
(1,3-dihydroxy-2-propoxymethylguanine [DHPG]), a nucleotide analog that spe-
cifically inhibits HCMV viral DNA replication (48), was from Syntex Inc. (Palo
Alto, Calif.). Bisindolylmaleimide I, a specific inhibitor of PKC (74), verapamil,
an inhibitor of calcium flux (4), and the PI3-K kinase inhibitors LY294002
[20(4-morphodinyl)-8-phenyl-1(4H)-benzopyran-4-one] (40, 80) and wortman-
nin (55, 76) were from Sigma (St. Louis, Mo.). DHPG was dissolved in water, and
verapamil was dissolved in ethanol. All other compounds were dissolved in
dimethyl sulfoxide. Unless otherwise indicated, the chemical compounds were
used at the following final concentrations: SB202190 (10 mM), rapamycin (10
nM), DHPG (20 mM), LY294002 (20 mM), bisindolylmaleimide I (200 nM),
verapamil (50 mg/ml), and wortmannin (100 nM). PI-3,4-P2 and PI-3,4,5-P3 were
each used at a final concentration of 10 mM.
Cell culture and viral infection. Human embryonic lung (HEL) fibroblasts
were cultured as previously described (33). All experiments were done using
HEL fibroblasts that were between passages 15 and 21. HCMV (Towne strain,
passages 39 to 42) was also propagated as previously described (31). For infec-
tion, cells were grown to confluence and then were serum starved for 48 h in
minimal essential media (MEM) plus antibiotics. Cells were infected with
HCMV that had been purified through a sucrose cushion to eliminate cytokines
and growth factor contamination. Unless otherwise indicated, a multiplicity of
infection of 5 PFU per cell was used. Where indicated, virus was UV irradiated
as previously described to prevent viral protein synthesis following infection (10,
84). At the indicated time after infection, cells were washed once and then were
maintained in MEM plus antibiotics until they were harvested. If the infection
was performed in the presence of chemical compounds, cells were pretreated for
1 h with the compound prior to infection. In addition, the compound was present
during infection and subsequent incubation periods. Mock-infected samples
were treated and harvested in the same manner as the infected samples except
that MEM without virus was used during the infection. For all experiments, the
time at which virus was first added to the cells is the zero hour.
Immunoprecipitations. Fibroblasts were harvested in lysis buffer (150 mM
NaCl, 20 mM Tris-HCl [pH 7.5], 1.0% Triton X-100, 0.5 mM EDTA, 50 mM
NaF, 10% glycerol, 20 mg of leupeptin/ml, 20 mg of phenylmethylsulfonyl fluoride
[PMSF]/ml, and 1 mM sodium vanadate) and incubated on ice for 10 min with
occasional vortexing. Cells were then frozen and stored at 270°C until the time
course was completed. Cells were then thawed, and debris was removed by
centrifugation (15,000 3 g for 10 min at 4°C). Protein concentration was deter-
mined using the Bio-Rad Protein Assay according to the manufacturer’s proto-
col. Five hundred micrograms of whole-cell extract (total volume of 500 ml) was
mixed with phosphotyrosine monoclonal PY20 antibody (1:50 dilution) and
rocked overnight at 4°C. Twenty milliliters of protein G-Sepharose was then
added, and rocking was allowed to continue for another 90 min. Beads were then
washed four times with lysis buffer. Twenty microliters of 23 sodium dodecyl
sulfate (SDS)-lysis buffer was added to the beads and boiled for 3 min. The
insoluble material was removed by centrifugation in a microcentrifuge, and the
supernatant was then subjected to Western blot analysis as described below.
Western blot analysis. Phosphotyrosine antibody (PY20) was from Santa Cruz
(Santa Cruz, Calif.). All other phosphospecific antibodies were from New En-
gland Bio-Labs (Beverly, Mass.). The polyclonal PI3-K antibody was from Up-
state Biotechnology Inc. (Lake Placid, N.Y.). The UL44 monoclonal antibody
was from Fitzgerald Industries International (Concord, Mass.). Monoclonal an-
tibodies to the protein products of the IE1-72, IE2-86, UL84, and UL94 viral
genes were prepared in our laboratory and have been described (27, 43, 81).
Western blot analysis was performed as previously described. Briefly, confluent
cells were infected as described above. At the indicated times, cells were har-
vested in 23 Laemmli SDS sample buffer, boiled, and loaded onto SDS-poly-
acrylamide gels. Proteins were separated by electrophoresis and transferred
overnight at 14 V to Immobilon-P Transfer Membrane (Millipore, Bedford,
Mass.). Blots were blocked for 30 min in 10% (wt/vol) Carnation nonfat dry milk
dissolved in phosphate-buffered saline (PBS) plus 0.1% Tween 20 (PBST). Blots
were then probed with primary antibody for 2 h at room temperature or over-
night at 4°C in PBST. Blots were washed three times with PBST. After washing,
the blots were probed with secondary antibody (horseradish peroxidase-conju-
gated anti-mouse or anti-rabbit immunoglobulin G [Sigma and New England
Bio-Labs, respectively]) for 1 h at room temperature. Blots were washed three
times in PBST and then developed by enhanced chemiluminescence according to
the manufacturer’s protocol (New England Bio-Labs).
Nuclear extract isolation. The nuclear extracts were prepared as previously
described (84, 85). Briefly, mock-infected or infected HEL fibroblasts were
washed in cold PBS, harvested using a rubber cell scraper, and centrifuged to
collect the cell pellet. The cell pellets were then incubated for 5 min on ice with
a cytoplasmic isolation buffer (10 mM HEPES [pH 7.6], 60 mM KCl, 1 mM
EDTA, 0.1% NP-40, 1 mM dithiothreitol, 1 mM PMSF [Sigma], 2 mM phenan-
throline [Sigma], 0.25 mM dichloroisocoumarin [Sigma], 100 mM E-64 [Sigma],
and 10 mM pepstatin A [Sigma]). The samples were centrifuged, and the nuclear
pellets were collected by removing the supernatant containing the cytoplasmic
extract. The nuclear pellets were then washed in cytoplasmic isolation buffer
without NP-40, centrifuged, and incubated for 10 min on ice with a nuclear
isolation buffer (20 mM Tris-HCl [pH 8.0], 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 0.5 mM PMSF, 25% glycerol, 2 mM phenanthroline [Sigma], 0.25
mM dichloroisocoumarin, 100 mM E-64, and 10 mM pepstatin A). Following
centrifugation, the supernatant was collected and stored in aliquots at 270°C.
EMSAs. The electrophoretic mobility shift assays (EMSAs) were performed as
previously described (84, 85). Briefly, collected nuclear extracts were incubated
for 15 min in a binding buffer (10 mM Tris-HCl [pH 7.9], 50 mM NaCl, 0.5 mM
EDTA, 10% glycerol, 1 mM dithiothreitol), 7.5 mM MgCl2, 0.1 mg poly(dIdC),
and a 32P-labeled wild-type major histocompatibility complex kB binding site
(59-CCTTTTTTTTTGGGGATTCCCCA-39) or a mutant kB binding site (59-C
CTTTTTTTTTGCGGCTTCCCGA-39) double-stranded oligonucleotide probe
for experiments examining NF-kB activity (mutated nucleotides are italicized).
The annealed double-stranded oligonucleotide probes with T overhangs and C
ends were labeled by filling in the recessed 39 ends of the oligonucleotide with
[a-32P]dATP (ICN, Irvine, Calif.) using Klenow enzyme (Boehringer Mannheim,
Indianapolis, Ind.), followed by a chase with cold dATP and dGTP, and then
were finally G-25 Sephadex (Boehringer Mannheim) column purified. The sam-
ples were electrophoresed on a 5% polyacrylamide gel, dried, and developed
with intensifier screens at 270°C. Antibodies were used to supershift the specific
complexes of interest by pretreating the extracts for 30 min to 1 h at 4°C with 1
mg of antibody prior to their addition to the binding buffer, MgCl2, dIdC, and
VOL. 75, 2001 ROLE OF PI3-K ACTIVITY IN HCMV INFECTION 6023
labeled probes. Specific antibodies to p50 and p65 of NF-kB (a generous gift
from Albert S. Baldwin, Jr. [18, 65]) were used in the supershift experiments.
Titer reduction assay. Titer reduction assays were performed as previously
described (34). Briefly, confluent HEL fibroblasts were infected as described
above in the presence of the indicated concentration of inhibitor compound. To
maintain a stable concentration of inhibitor, fresh media containing appropriate
concentrations of inhibitor were added every 48 h. At day 6 postinfection, the
supernatant was harvested and used to perform an HCMV standard plaque assay
in the 24-well plate using 1% methyl cellulose overlayer containing 13 MEM and
4% fetal bovine serum. HCMV plaque numbers were scored under an inverted
microscope.
Dot blot analysis. Dot blot analysis was performed as previously described
(34). Briefly, cells were grown to confluence, serum starved, and infected with
HCMV at a multiplicity of infection of 5 PFU per cell. Cells were harvested at
the indicated times postinfection, and dot blot hybridization was performed using
32P-radiolabeled, purified, genomic HCMV DNA as a probe (34). After washing,
the radioactivities on the membranes were detected by autoradiography using
Kodak X-ray films. The intensity of radioactive exposure is correlated to the
amount of viral DNA on the membrane.
RESULTS
Effect of HCMV infection on PI3-K activity. The first step in
this study was to determine the effect of HCMV infection on
PI3-K activity by examining phosphorylation of the p85 subunit
of PI3-K, which correlates with PI3-K kinase activity in vivo
(23, 54, 70). Confluent, serum-starved HEL fibroblasts were
infected with HCMV and harvested at the indicated times. p85
phosphorylation was determined by immunoprecipitation us-
ing a phosphotyrosine antibody (PY20; Santa Cruz), followed
by Western blot analysis using an antibody specific for p85.
Figure 1A demonstrates that between 15 and 30 min after the
addition of HCMV, p85 phosphorylation increased dramati-
cally (lanes 3 and 4). This activation was transient, and by 2
hpi, p85 phosphorylation declined to a level close to that ob-
served in 0-h cells and in mock-infected cells (lanes 2 and 5).
However, beginning at 4 hpi, a second tier of PI3-K phosphor-
ylation was observed, and this increase was sustained for the
remainder of the infection (lanes 6 to 9). Further Western blot
analysis showed that the overall level of p85 remained stable
throughout infection, indicating that the changes in phosphor-
ylation were not due to changes in the overall level of p85 (Fig.
1A, bottom).
Activation of cellular Akt and p70S6 kinases by PI3-K. To
assess whether PI3-K was involved in cellular signaling during
HCMV infection, we examined activation of the cellular ki-
nases Akt and p70S6K, both of which can be activated in a
PI3-K-dependent manner. First, the effect of HCMV infection
on Akt activity was examined by Western blot analysis using an
Akt phosphospecific antibody (no. 9275; New England Bio-
Labs). This antibody recognizes only Akt that is phosphory-
lated on Ser 473, which has been shown to correlate extremely
well with Akt kinase activity and provides a convenient, reli-
able method to analyze AKT activity (3, 7). Western blot anal-
ysis indicated that Akt was activated in a two-tiered manner
following HCMV infection (Fig. 1B). In addition, the time
course of Akt activation mirrored that of PI3-K (compare Fig.
1A and B). The amount of total Akt protein remained constant
throughout infection, indicating that the changes in Akt phos-
phorylation were not due to changes in protein levels (Fig. 1B,
bottom).
Next, the activation of p70S6K in HCMV-infected fibro-
blasts was examined. Again, Western blot analysis was per-
formed using a phosphospecific antibody that recognizes
p70S6K only if it is phosphorylated on Thr 389. This phosphor-
ylation is dependent upon PI3-K activity and is indicative of
p70S6K activity (53, 57, 72). Figure 1C demonstrates that, as
with Akt, p70S6K activation following HCMV infection was
two-tiered and mirrored PI3-K activation.
FIG. 1. Activation of PI3-K, Akt, and p70S6K following HCMV infection. HEL fibroblasts were grown to confluence, serum starved for 48 h,
infected with HCMV, and harvested at the indicated times postinfection. (A) Active p85 was immunoprecipitated from equal amounts of infected
whole-cell lysate (500 mg) by using a phosphotyrosine antibody, PY20 (Santa Cruz). The amount of immunoprecipitated protein was determined
by Western blot analysis using a primary antibody that recognizes total p85 (Upstate Biotechnology). Western blot analysis of whole-cell extracts
using a p85 antibody showed that the overall level of p85 does not fluctuate during infection (bottom). (B) Western blot analysis of whole-cell
extracts probed with either phosphospecific (to demonstrate Akt activation) or nonphosphospecific (to demonstrate that overall levels of Akt are
equal) Akt antibodies, a-phosphoAkt (Ser 473 [top]) and a-Akt (bottom), respectively. (C) Mock-infected and HCMV-infected whole-cell extracts
were studied for p70S6K activation by Western blot analysis using either a phosphospecific p70S6K antibody which recognized only the active form
of p70S6K (top) or an antibody which recognized all forms of p70S6K (bottom). Each experiment was performed a minimum of five times, and
representative results are shown. Ser 473 and Thr 389 are the phosphorylated residues which are recognized by the phosphospecific antibodies.
Mock, mock-infected HEL fibroblasts; Phos, phosphorylated.
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The first tier of activation of cellular kinases does not re-
quire viral protein synthesis. To further characterize HCMV-
mediated activation of PI3-K, p70S6K, and Akt, fibroblasts
were infected with virus stock that was UV irradiated prior to
infection. UV irradiation creates thymidine dimers, which pre-
vent transcription of viral genes without inhibiting the ability of
the virus to bind to and enter the host cell. Interestingly,
following infection of fibroblasts with UV-irradiated virus, ac-
tivation of PI3-K, Akt, and p70S6K was detected at 15 to 30
min postinfection (Fig. 2A to C, lanes 1 to 4). However, by 2
hpi, the activity of all three kinases had declined to preinfec-
tion levels and no further activation of these kinases was de-
tected (lanes 5 to 9). These data indicate that while viral
protein expression is not required for the first tier of activation
(15 to 30 min postinfection), it is necessary for the second tier
of activation (beginning at 4 hpi).
Activation of p70S6K and Akt is dependent on PI3-K kinase
activity. The chemical compound wortmannin is a potent, spe-
cific, cell-permeable inhibitor of PI3-K activity (55, 76). To
determine if HCMV-mediated activation of Akt and p70S6K
was dependent upon PI3-K activity, cells were treated with
wortmannin during infection. Figure 3A and B demonstrate
that in the presence of wortmannin, no Akt or p70S6K activa-
tion was detected at early times of infection. This indicates that
PI3-K activity is required for HCMV-mediated activation of
Akt and p70S6K.
To determine if PI3-K activity was necessary for this second
tier of Akt and p70S6K activation, infected fibroblasts were
treated with the chemical compound LY294002. Like wort-
mannin, LY294002 is a potent and specific inhibitor of PI3-K
activity, but it is much more stable at 37°C than wortmannin
and is therefore better suited for studies that require inhibiting
PI3-K activity for an extended time. As Fig. 4A and B illus-
trate, treatment of infected cells with LY294002 completely
inhibits virus-mediated p70S6K and Akt activation. LY294002
has been found to be an extremely potent and specific inhibitor
of PI3-K activity (40, 80). However, as with any inhibitor com-
FIG. 2. Activation of PI3-K, Akt, and p70S6K following infection
with UV-irradiated virus. HEL fibroblasts were grown to confluence,
serum starved for 48 h, infected with HCMV, and harvested at the
indicated times postinfection. HEL fibroblasts were infected with the
HCMV Towne strain, which was UV irradiated prior to infection to
prevent viral gene expression. Cells were harvested and analyzed for
phosphorylated (top) and total (bottom) PI3-K (A), Akt (B), and
p70S6K (C) activations as described for Fig. 1. (D) Western blot
analysis was also performed, using an antibody to the HCMV IE1-72
protein to demonstrate that viral proteins were not being expressed
following infection with UV-irradiated virus. Representative results
from four separate experiments are shown. Ser 473 and Thr 389 are the
phosphorylated residues which are recognized by the phosphospecific
antibodies. Mock, mock-infected HEL fibroblasts; Phos, phosphory-
lated.
FIG. 3. Inhibition of p70S6K and Akt activation by PI3-K inhibi-
tors. HEL fibroblasts were grown to confluence, serum starved for
48 h, infected with HCMV, and harvested at the indicated times
postinfection. Shown are inhibitions of Akt (A) and p70S6K (B) acti-
vation at early times of HCMV infection by wortmannin. Fibroblasts
were pretreated and treated with 100 nM wortmannin prior to and
during infection. Cells were harvested and whole-cell extract was
probed for activated and total Akt and p70S6K as described for Fig. 1.
(C) LY294002 inhibits HCMV-mediated p70S6K activation. HEL fi-
broblasts were pretreated with inhibitors (LY294002 [LY], bisindolyl-
maleimide I [Bis], verapamil, and SB202190 [SB90]), infected, and
harvested at 12 hpi. p70S6K activation was determined by Western blot
analysis (top). Note that only the PI3-K inhibitor LY294002 inhibited
p70S6K phosphorylation. The extracts were then probed for total
p70S6K to show that the overall levels of p70S6K were not altered by
viral infection. Due to the percentage of polyacrylamide in the gel that
was used, it is possible to distinguish the unphosphorylated form of
p70S6K (lower bands) from the phosphorylated forms (upper bands)
in the lower panel. Each experiment was performed a minimum of
three times, and representative results are shown. Ser 473 and Thr 389
are the phosphorylated residues which are recognized by the phos-
phospecific antibodies. Mock, mock-infected cells; Inf, infection.
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pound, the possibility of nonspecific inhibition of cellular or
viral enzymes remains. The two main products of active PI3-K
are PI-3,4-P2 and PI-3,4,5-P3. We reasoned that if the effect of
LY294002 on HCMV-mediated Akt and p70S6K activation
was due to inhibition of PI3-K activity, adding PI-3,4-P2 and
PI-3,4,5-P3 to infected fibroblasts treated with LY294002
should permit activation of Akt and p70S6K. This possibility
was tested experimentally. As can be seen in Fig. 4B and C,
infected cells treated with PI-3,4-P2, PI-3,4,5-P3, and
LY294002 had a high level of Akt and p70S6K activation,
indicating that the effect of LY294002 on these kinases is
mediated by inhibition of PI3-K activity.
Regulation of p70S6K is very complex and requires kinases
in addition to PI3-K. To better characterize p70S6K activation
following HCMV infection, cells were infected in the presence
of compounds that have been shown to inhibit different
p70S6K activation pathways in other systems. Figure 3C illus-
trates that while LY294002 inhibited p70S6K activation (lane
3), none of the other inhibitors tested—SB202190 (p38 MAPK
inhibitor), bisindolymaleimide I (PKC inhibitor), or verapamil
(calcium flux inhibitor)—affected p70S6K activation (Fig. 3C,
lanes 4, 5, and 6). Thus, these pathways are likely not involved
in HCMV-mediated activation of p70S6K.
Effect of PI3-K inhibitors on HCMV-mediated NF-kB acti-
vation. There have been several reports that the transcription
factor NF-kB can be activated in a PI3-K-dependent manner
(9, 37, 47, 58, 62). Since NF-kB is activated during HCMV
infection and this activation is thought to be an important
signaling event during HCMV infection, the effect of wortman-
nin and LY294002 on HCMV-mediated NF-kB activation was
examined (42, 64, 85). Quiescent fibroblasts were infected in
the presence or absence of PI3-K inhibitors. At the indicated
times, cells were harvested, nuclear extracts were isolated, and
NF-kB activation was assessed by EMSA analysis. As has been
previously reported, HCMV induced a two-tiered activation of
NF-kB (Fig. 5A) (84, 85). Interestingly, as with p70S6K and
Akt, inhibition of PI3-K activity by either wortmannin or
LY294002 completely inhibited both the first tier and the sec-
ond tier of NF-kB activation (Fig. 5B and C and data not
shown). This series of experiments suggest that PI3-K is a
major mediator of HCMV-induced signaling during infection.
Effect of LY294002 on HCMV lytic life cycle. To determine
if PI3-K signaling was important for completion of the viral life
cycle, a titer reduction assay was performed in the presence of
LY294002. Figure 6A illustrates the effect of different concen-
trations of LY294002 on viral titers at day 6 postinfection. A
significant decrease in viral titers was observed with concen-
trations of inhibitor as low as 1 mM. At a concentration of 5
mM, viral titers were decreased by more than 95% compared to
those of control titers, and at 20 mM, viral titers were de-
creased by greater than 4 logs. Next, viral DNA replication in
the presence of LY294002 was assessed by dot blot analysis.
Figure 6B demonstrates that treatment with LY294002 signif-
icantly inhibited viral DNA replication.
PI3-K regulates many important cellular processes, and in
certain cell types, inhibition of PI3-K activity causes cell death
(68, 82). While infected fibroblasts treated with LY294002 had
altered morphology, no apoptosis was detected by propidium
iodide staining and flow cytometry analysis (data not shown).
To demonstrate that these cells were capable of supporting
viral DNA replication, fibroblasts were infected in the pres-
ence of LY294002 for 96 h, after which the inhibitor was
removed and the infection was allowed to proceed for an
additional 24 h. Cells were then harvested and analyzed for
viral DNA replication by dot blot analysis. Figure 6C shows
that after LY294002 was removed, high levels of viral replica-
FIG. 4. Both tiers of HCMV-mediated activation of p70S6K and Akt are dependent upon PI3-K kinase activity. HEL fibroblasts were grown
to confluence, serum starved for 48 h, infected with HCMV, and harvested at the indicated times postinfection. HEL fibroblasts were infected with
only HCMV (A), infected in the presence of the PI3-K inhibitor LY294002 (20 mM) (B), or infected in the presence of LY294002 (20 mM) and
the products of activated PI3-K, PI-3,4-P2, and PI-3,4,5-P3 (each at 10 mM) (C). Cells were harvested and were analyzed for Akt and p70S6K
activation as shown in Fig. 1. Representative results from three independent experiments are shown. Phos, phosphorylated.
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tion were detected. In addition to demonstrating that
LY294002-treated fibroblasts can still support viral DNA rep-
lication, this also indicates that the effect of inhibiting PI3-K
kinase activity on viral DNA replication is reversible.
Again, PI-3,4-P2 and PI-3,4,5-P3 were utilized to demon-
strate the specificity of LY294002. As can be seen in Fig. 6D,
while LY294002 treatment inhibited viral DNA replication
(lane 3), treatment with PI-3,4-P2, PI-3,4,5-P3, and LY294002
yielded high levels of viral DNA replication which were com-
parable to those of control infections (lane 4). This indicates
that the effect of LY294002 on viral DNA replication is indeed
due to inhibition of PI3-K kinase activity.
Effect of rapamycin on viral life cycle. p70S6K regulates
translation of mRNAs by phosphorylating, and hence activat-
ing, the ribosomal S6K subunit (56, 57). We hypothesized that
the function of PI3-K during HCMV infection is to ensure
activation of p70S6K, which in turn would ensure translation of
various viral and cellular mRNAs necessary for completion of
the viral life cycle. To test this hypothesis, the small molecule
rapamycin, which inhibits p70S6K activation or phosphoryla-
tion without affecting PI3-K activity, was utilized in a titer
reduction assay (13, 17, 20, 26, 71). As can be seen in Fig. 7A,
rapamycin had no significant effect on viral titers. Further-
more, no effect on viral DNA replication was observed with
rapamycin (Fig. 7B). Viral L gene expression does not occur
until after viral DNA replication. To provide further evidence
that viral DNA replication was not inhibited by rapamycin
treatment, cells were infected for 96 h in the presence of
rapamycin, harvested, and assayed for expression of the true L
gene UL94 by Western blot analysis. Figure 7C demonstrates
that, even with 100 nM rapamycin, no significant decrease in
UL94 expression was observed (top). Further Western blot
analysis shows that 10 nM rapamycin still inhibited HCMV-
mediated p70S6K activation, indicating that the results ob-
tained in Fig. 7A and B were not due to a loss of rapamycin
activity (Fig. 7C, middle, compare lanes 2 with lanes 5 to 7).
These data suggest that under these experimental conditions,
HCMV-mediated p70S6K activation is not required for
HCMV to complete its viral life cycle in a timely manner. Also,
the antiviral effects of LY294002 are not due to inhibition of
p70S6K activation.
Effect of LY294002 and rapamycin on viral gene expression.
To further characterize the role of PI3-K in the viral life cycle,
the effect of LY294002 and rapamycin on protein levels of viral
IE, E, and L genes was examined by Western blot analysis.
Figure 8A and B show that treatment of fibroblasts with
LY294002 decreased the levels of the two major IE proteins,
IE1-72 and IE2-86, at early (4 and 8 hpi) and late (24 to 48 hpi)
times of virus infection, compared to cells infected in the ab-
sence of the compound. Ly294002 also strongly inhibited ex-
pression of the E genes UL44 (DNA polymerase processing
factor) and UL84, both of which are required for initiation of
viral DNA replication (27, 52, 79). Interestingly, rapamycin did
not affect the level of viral IE or E proteins at early or late
times of infections.
Finally, expression of the true L gene UL94 was examined
(Fig. 8C). High levels of UL94 protein were detected by 96 h
in infected control cells and in cells infected in the presence of
rapamycin (lanes 2 and 5). In contrast, UL94 protein was
barely detected in cells treated with LY294002 (lanes 3 and 4).
Since late gene expression cannot occur until after initiation of
viral DNA replication, this result supports the data presented
in Fig. 6 and 7B, which show that LY294002, but not rapamy-
cin, inhibits viral DNA replication.
DISCUSSION
PI3-K activation following HCMV infection. It is well doc-
umented that following infection, HCMV induces activation of
many host cell transcription factors and proteins involved in
DNA replication (21, 30, 50, 77, 86). However, the upstream
cellular signaling pathways involved in this activation remains
FIG. 5. Inhibition of HCMV-mediated NF-kB activation by wortmannin. HEL fibroblasts were grown to confluence, serum starved for 48 h,
infected with HCMV, and harvested at the indicated times postinfection. Fibroblasts were infected in the presence or absence of wortmannin (100
nM), and nuclear extracts were harvested at the indicated times as described in Materials and Methods. NF-kB activation was measured by EMSA.
Note that wortmannin inhibits both the first tier (10 to 30 min postinfection) and the second tier (4 hpi) of NF-kB activation. Locations of p50-p50
and p50-p65 homodimers and heterodimers were confirmed by supershift analysis using specific antibodies (data not shown). Each experiment was
performed three times, and representative results are shown.
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for the most part unknown. Initially, we found that PI3-K is
activated immediately after the addition of HCMV to resting
fibroblasts (Fig. 1A). This finding raises many questions. First,
what viral processes are responsible for PI3-K activation? The
results obtained with the UV-irradiated virus indicates that
viral protein expression is not required to obtain the first tier of
HCMV-mediated PI3-K activation (Fig. 2A and D). Other
studies have shown that binding of viral glycoproteins located
in the virion to host cell receptors activates cellular signaling
pathways (12, 86). This receptor-ligand interaction results in
activation of a number of cellular proteins, including the
NF-kB and Sp-1 transcription factors, the ERK1/2 MAPK
pathway, and several genes in the interferon response pathway
(12, 35, 84, 86). The fact that this receptor-ligand interaction is
sufficient to obtain the first tier of NF-kB activation, that PI3-K
activation is required for NF-kB activation, and that UV-irra-
diated virus is sufficient to activate PI3-K (Fig. 2A and 5B) all
suggest that binding of virion glycoprotein to host cell recep-
tors may be sufficient to obtain the first tier of PI3-K activation.
We are currently performing experiments to specifically ad-
dress this possibility.
The fact that the appearance of the second tier of PI3-K
activation requires viral protein expression (Fig. 2 and 4) in-
dicates that different viral processes are involved in the two
tiers of HCMV-mediated PI3-K activation. The observation
that the second tier of PI3-K activation correlates with the
increase in IE protein levels suggests that IE proteins may be
involved in the second tier of PI3-K activation. Hopefully,
future experiments will determine if this is indeed the case.
Another question raised by this initial finding is what cellular
kinases or regulators are upstream of HCMV-mediated PI3-K
activation. In most of the cases, PI3-K activation is triggered
when activated cell surface receptors and associated tyrosine
kinases recruit heterodimeric PI3-Ks, which consists of a p110
catalytic subunit and a p85 adapter molecule that contains
Src-homology 2 (SH2) and SH3 domains (23, 24, 70). The SH2
domains are essential for mediating the interaction between
p85 and the specific phosphotyrosine (pTyr) residues that are
located on PI3-K substrate proteins (24, 87). This SH2-pTyr
interaction brings the substrate (which is now bound to p85)
into close proximity to the p110 catalytic subunit of PI3-K,
which in turn increases the rate of substrate phosphorylation
(16, 24).
The kinase activity of PI3-K can also be directly activated by
FIG. 6. Antiviral effects of LY294002 on HCMV lytic life cycle. HEL fibroblasts were grown to confluence, serum starved for 48 h, infected with
HCMV, and harvested at the indicated times postinfection. (A) Viral titers are reduced in the presence of LY294002. Confluent, serum-starved
fibroblasts were pretreated with LY294002 and then were infected with HCMV in the presence of LY294002. Six days after infection, supernatant
was harvested and a standard HCMV plaque assay was performed to determine the infectious virus titer. The graph shows the relative number
of plaques in each sample, where 100% is the infectivity of supernatant harvested from cells infected in the absence of LY294002. Each sample
was done in triplicate, and the entire assay was performed three times. Error bars represent the standard deviation for the experiment. (B to D)
Effect of LY294002 on viral DNA replication. Confluent, serum-starved fibroblasts were infected with HCMV in the presence of the indicated
chemical compounds. Where indicated, LY294002 was removed from the culture media at 96 hpi, and the infection was allowed to continue for
an additional 24 h. Cells were harvested at 96 hpi (B and D) or 120 hpi (C) and were analyzed for total viral DNA by dot blot hybridization. DHPG
was used as a positive control. PI-3,4-P2 and PI-3,4,5-P3 are the lipid products of active PI3-K and were used to demonstrate that the inhibition
of viral DNA replication by LY294002 is due to inhibition of PI3-K activity. (A to C) Each experiment was performed a minimum of three times,
and representative results are shown. (D) Results from two separate experiments are shown. Dot blot analysis was viewed on X-ray film. DHPG,
ganciclovir; inf, infection; mock, mock-infected cells.
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the small G protein Ras (49). Ras binds to the p110 subunit of
PI3-K in a GTP-dependent manner, which results in an in-
crease in PI3-K activity (60, 61). Thus, the full activation of
PI3-K requires concurrent association of the catalytic subunit
(p110) with Ras and the adapter unit (p85) with a pTyr-con-
taining protein. Furthermore, in antigen-receptor complex
pathways, PI3-K can be also activated by Src family kinases
through the SH3 domain of the p85 subunit (54). The data
presented in this study suggest that both tiers of PI3-K activa-
tion observed following HCMV infection are mediated at least
in part by increased phosphorylation of the p85 subunit (Fig.
1A). Currently, we are utilizing specific inhibitors to determine
if other events are required for each tier of PI3-K activation
following HCMV infection. These ongoing studies should pro-
vide new insight into the mechanism of virus-mediated PI3-K
activation.
PI3-K signaling in infected fibroblasts. While activation of
NF-kB following HCMV infection is well documented, this is
the first report of Akt and p70S6K activation following viral
FIG. 7. Rapamycin does not affect viral titers, viral DNA replica-
tion, or viral late gene expression. HEL fibroblasts were grown to
confluence, serum starved for 48 h, infected with HCMV, and har-
vested at the indicated times postinfection. Fibroblasts were infected in
the presence of the indicated concentrations of rapamycin, harvested,
and assayed for titer reduction (A) or dot blot analysis (B) as described
for Fig. 6. Dot blot analysis was viewed by X-ray film. (C) Rapamycin
inhibits HCMV-mediated p70S6K activation but does not inhibit
UL94 expression. Cells were infected in the presence or absence of
rapamycin or LY294002 (positive control). At 96 hpi, cells were har-
vested and Western blot analysis was performed using a monoclonal
antibody to the viral true late protein UL94 (top). Western blot anal-
ysis for p70S6K activation was performed on the same lysate described
for Fig. 1. Western blot analysis of b-actin levels demonstrated equal
protein loading between samples. Phos, phosphorylated.
FIG. 8. Expression of viral proteins in the presence of LY294002
and rapamycin. HEL fibroblasts were grown to confluence, serum
starved for 48 h, infected with HCMV, and harvested at the indicated
times postinfection. Serum-starved HEL fibroblasts were infected in
the presence or absence of 20 mM LY294002 or 10 nM rapamycin.
Cells were harvested and analyzed for viral protein expression by
Western blot analysis. Western blot analyses were performed (i) with
antibodies to the IE proteins (IE1-72 and IE2-86) and early proteins
(UL44 and UL84) at 4 and 8 hpi (A) and at 24 and 48 hpi (B) and (ii)
on late protein UL94 synthesis at 96 hpi (C). Each experiment was
performed at least three times, and representative results are shown.
In each case, b-actin levels were determined by Western blot analysis
to demonstrate equal protein concentrations between samples.
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infection (11, 42, 83, 85). Furthermore, this study is the first to
show that Akt, p70S6K, and NF-kB are all activated in a
PI3-K-dependent manner during HCMV infection (Fig. 1 to
5). Akt was originally identified as a downstream target of
PI3-K by overexpression of dominant-negative proteins and by
the use of PI3-K inhibitors, such as LY294002 and wortmannin
(22, 40, 41). Recent reports have demonstrated that PI3-K-
mediated activation of Akt can inhibit apoptosis induced by a
wide range of apoptotic stimuli (36). Based on these reports,
we speculated that Akt was serving an antiapoptotic role in
HCMV-infected fibroblasts. However, this proved not to be
the case, as no apoptosis was detected in infected cells treated
with LY294002 (Fig. 6C and data not shown). Several HCMV-
encoded proteins have been shown to block apoptosis induced
by various stimuli, such as overexpression of adenovirus E1A
or activation of cell death receptors (25, 88). It is possible that
HCMV-mediated activation of Akt is important for one or
more of these antiapoptotic functions. This, in turn, would
allow HCMV to complete its lytic life cycle and release infec-
tious particles before cell death occurred.
PI3-K-mediated activation of p70S6K has also been well
studied, so the finding that p70S6K was activated in a PI3-K-
dependent manner was not unexpected (19, 23, 75, 76). The
results obtained by treating infected cells with rapamycin,
which inhibits p70S6K activation independent of PI3-K, sug-
gests that under our conditions, p70S6K activity is not required
for completion of the viral lytic life cycle (Fig. 7 and 8).
Several laboratories have reported that PI3-K can regulate
activation of NF-kB (9, 47, 58, 59, 62). The exact mechanism of
this activation is still somewhat uncertain, due in part to the
fact that NF-kB activity is regulated by multiple mechanisms.
In unstimulated cells, the classic NF-kB heterodimer, com-
posed of a p65 subunit and a p50 subunit, is found in the
cytoplasm bound to an inhibitor molecule, termed IkB (6). IkB
is bound to the nuclear localization signal of NF-kB, which
prevents NF-kB from translocating to the nucleus. Upon stim-
ulation, a kinase pathway is activated, which results in phos-
phorylation and subsequent ubiquitin-mediated degradation of
IkB (6). This allows NF-kB to translocate to the nucleus,
where it binds DNA and activates expression of cellular genes,
many of which are involved in inhibition of apoptosis (62). It
was recently discovered that the transactivation function of the
p65 subunit can also be regulated by phosphorylation, which is
independent of p65 DNA binding (47, 78). Depending upon
the stimuli and cell type, PI3-K can activate NF-kB through
either mechanism. In addition, activation of Akt by PI3-K is
thought to be a critical event in both types of activation. How
does this relate to HCMV-mediated NF-kB activation? It has
been demonstrated that HCMV infection enhances NF-kB
transactivation function by both promoting homodimer and
heterodimer formation and increasing the overall level of sub-
unit protein by increasing mRNA levels (42, 85). Both the first
and second tiers of NF-kB activation correlate with a decrease
in IkB protein levels (data not shown). To date, however, we
have been unable to detect p65 phosphorylation following
HCMV infection. Based on the fact that PI3-K has been shown
to induce IkB degradation, we hypothesize that at least one
function of PI3-K activity in NF-kB activation is to induce
phosphorylation and degradation of IkB. Studies in progress
will show if this is indeed the case and also whether PI3-K
activity alters the ability of HMCV to increase transcription of
NF-kB. Furthermore, studies using the dominant-negative Akt
should provide evidence as to the role of Akt activity, if any, in
PI3-K-mediated NF-kB activation during HCMV infection.
The function of NF-kB in HCMV infection remains to be
determined. Activation of NF-kB can protect cells from a
variety of different types of apoptosis (47, 49). However, since
HCMV-infected fibroblasts did not undergo apoptosis in the
presence of LY294002, this is not a function of NF-kB in these
cells. As is the case with Akt, it is also very possible that under
other environmental conditions, HCMV-mediated activation
of NF-kB may protect infected cells from apoptosis. Previ-
ously, our laboratory and others have speculated that NF-kB
activation is important for expression of the major IE pro-
moter, which encodes IE1-72 and IE2-86 (32, 42, 64, 85).
Under the experimental conditions used in this study, inhibi-
tion of PI3-K resulted in very significant reductions in IE1-72
and IE2-86 protein levels. By inhibiting NF-kB activation in
HCMV-infected cells, we hope to determine if this impact of
LY294002 on IE gene expression is due to its effect on NF-kB
activation. In addition, these studies will also demonstrate if
NF-kB has other roles in viral infection which have not been
identified.
Role of PI3-K in viral life cycle. Treatment of cells with
LY294002, but not rapamycin, inhibited viral IE1-72 and
IE2-86 expression, as well as viral DNA replication (Fig. 6 to
8). These results imply that PI3-K signaling is important for the
initiation of viral DNA replication and subsequent completion
of the viral lytic life cycle. Treatment of cells with LY294002 or
rapamycin also resulted in a very significant decrease in UL44
and UL84 protein levels. Preliminary results from our labora-
tory indicate that while LY294002 has a significant effect on
UL44 and UL84 mRNA levels, rapamycin has almost no effect
(data not shown). Based on these findings, we hypothesize that
PI3-K activity is required for optimal transcription and trans-
lation of at least IE genes and perhaps some E genes.
Viral IE proteins are required for expression of viral E genes
and initiation of viral DNA replication (50). Therefore, the
inhibition of viral DNA replication and E gene expression
observed with LY294002 is due at least in part to the significant
loss of IE gene expression. Since PI3-K activates many proteins
that are involved in DNA synthesis, we believe it likely that
PI3-K has other roles in regulating the initiation of viral DNA
replication besides regulating IE and E protein levels. For
example, perhaps in the presence of LY294002, cellular pro-
teins required for viral DNA replication are not being acti-
vated. We will try to determine if PI3-K has other functions in
HCMV infection by specifically inhibiting individual pathways
and proteins that are activated in a PI3-K-dependent manner
during HCMV infection, such as Akt and NF-kB, and exam-
ining the effect of this inhibition of viral DNA replication.
Using this approach, we have already demonstrated that PI3-
K-mediated activation of p70S6K does not affect viral DNA
replication or viral gene expression (Fig. 7 and 8).
Though many questions remain, this study has identified a
cellular kinase that both is an important mediator of viral
signaling and is required for viral DNA replication. By focusing
on PI3-K signaling in the future, we hope to more clearly
define the complex interaction between viral infection and the
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cellular signaling pathway that is required for successful com-
pletion of the lytic life cycle.
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